The European Commission has approved, under the EU Merger Regulation, the proposed acquisition of Acelity, Inc. (“Acelity”) by 3M Company (“3M”), both of the US. Acelity and 3M are both active in the supply of advanced wound care products.
In particular, they are active in the supply of moist advanced wound care products, which are medical devices that provide a moist environment that can encourage healing and tissue growth in wounds that have difficulty healing in normal conditions.
In addition, Acelity is a supplier of negative pressure wound therapy devices and kits and 3M is a supplier of film drapes and barrier films, which are used together with negative pressure wound therapy devices and included in certain kits.
The Commission concluded that the proposed transaction would raise no horizontal competition concerns given the companies’ moderate combined market shares in the supply of advanced wound care products (or any plausible sub-segmentations) and the presence of a number of competitors in these markets. Moreover, the Commission did not find any anti-competitive vertical or conglomerate effects resulting from the combination of these businesses.
Full Content: Europa
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.